Reason for request
Re-assessment of the Actual Benefit and Improvement in Actual Benefit in accordance with article R-163-21 of the Social Security Code.
Clinical Benefit
| Substantial |
The Actual Benefit of XEROQUEL LP in the treatment of schizophrenia is substantial. |
Clinical Added Value
| no clinical added value |
XEROQUEL LP does not provide an Improvement in Actual Benefit (IAB level V) compared with other treatments available in this indication. |
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
DXp7qatTmatLTZPv
